Titre : Hepatitis C Therapies Perform Well in Challenging Patients
link : Hepatitis C Therapies Perform Well in Challenging Patients
Hepatitis C Therapies Perform Well in Challenging Patients
Medscape Coverage fromDigestive Disease Week (DDW) 2017
Hepatitis C Therapies Perform Well in Challenging Patients
William F. Balistreri, MD
At this year's Digestive Disease Week, several studies looked into the nuances of treating hepatitis C virus (HCV)infection. Of particular interest were new data regarding difficult-to-treat groups and the validation of shorter, simpler regimens
Glecaprevir and PibrentasvirIn several phase 2 and 3 clinical trials, patients who received the pangenotypic direct-acting antivirals (DAAs) glecaprevir (GLE) and pibrentasvir (PIB) achieved sustained virologic response (SVR) rates of 92%-100% across all six major HCV genotypes...
Sofosbuvir/Velpatasvir/Voxilaprevir
A pangenotypic combination of sofosbuvir (SOF), velpatasvir (VEL), and voxilaprevir (VOX) was designed to inhibit three distinct HCV targets: the NS5B polymerase, the NS5A protein, and NS3/4A protease, respectively.
Flamm and colleagues[3] presented cumulative data from 1056 patients with and without compensated cirrhosis who were infected with HCV genotype 1-6 and treated with the once-daily fixed-dose combination tablet of SOF/VEL/VOX in phase 3 studies....
Continue reading....
Free registration required
Thus articles Hepatitis C Therapies Perform Well in Challenging Patients
that is all articles Hepatitis C Therapies Perform Well in Challenging Patients This time, hopefully can provide benefits to you all. Okay, see you in another article post.
You are now reading the article Hepatitis C Therapies Perform Well in Challenging Patients the link address https://newsaninpiration.blogspot.com/2017/07/hepatitis-c-therapies-perform-well-in.html
0 Response to "Hepatitis C Therapies Perform Well in Challenging Patients"
Post a Comment